Literature DB >> 27077687

SymptoMScreen: A Tool for Rapid Assessment of Symptom Severity in MS Across Multiple Domains.

R Green1, J Kalina1, R Ford2, K Pandey2, I Kister1,2.   

Abstract

The objective of this study was to describe SymptoMScreen, an in-house developed tool for rapid assessment of MS symptom severity in routine clinical practice, and to validate SymptoMScreen against Performance Scales (PS). MS patients typically experience symptoms in many neurologic domains. A tool that would enable MS patients to efficiently relay their symptom severity across multiple domains to the healthcare providers could lead to improved symptom management. We developed "SymptoMScreen," a battery of 7-point Likert scales for 12 distinct domains commonly affected by MS: mobility, dexterity, body pain, sensation, bladder function, fatigue, vision, dizziness, cognition, depression, and anxiety. We administered SymptoMScreen and PS scales to consecutive MS patients at a specialty MS Care Center. We assessed the criterion and construct validity of SymptoMScreen by calculating Spearmen rank correlations between the SymptoMScreen composite score and PS composite score, and between SymptoMScreen subscale and the respective PS subscale scores, where applicable. A total of 410 patients with MS (age 46.6 ± 12.9 years; 74% female; mean disease duration 12.2 ± 8.7 years) completed the SymptoMScreen and PSs during their clinic visit. Composite SymptoMScreen score correlated strongly with combined PS score (r = 0.88, p < 0.0001). SymptoMScreen sub scores correlated strongly with the criterion measures of the respective PS (r = 0.69-0.87, p < 0.0001). Test-retest reliability of SymptoMScreen and its subscales was excellent (r = 0.71-0.94, p < .0001). SymptoMScreen is a single-page battery of Likert scales that assesses symptom impact in 12 domains commonly affected in MS. It has excellent criterion and construct validity. SymptoMScreen is patient and clinician friendly, takes approximately one minute to complete, and can help better document, understand, and manage patients' symptoms in routine clinical practice. SymptoMScreen is freely available to clinicians and researchers.

Entities:  

Keywords:  Multiple Sclerosis; scale design; symptom validity testing

Mesh:

Year:  2016        PMID: 27077687     DOI: 10.1080/23279095.2015.1125905

Source DB:  PubMed          Journal:  Appl Neuropsychol Adult        ISSN: 2327-9095            Impact factor:   2.248


  10 in total

1.  Uptake and Attitudes About Immunizations in People With Multiple Sclerosis.

Authors:  Ruth Ann Marrie; Leanne Kosowan; Gary R Cutter; Robert Fox; Amber Salter
Journal:  Neurol Clin Pract       Date:  2021-08

2.  Disparities in Telehealth Care in Multiple Sclerosis.

Authors:  Ruth Ann Marrie; Leanne Kosowan; Gary Cutter; Robert Fox; Amber Salter
Journal:  Neurol Clin Pract       Date:  2022-06

3.  Attitudes toward coronavirus disease 2019 vaccination in people with multiple sclerosis.

Authors:  Ruth Ann Marrie; Casandra Dolovich; Gary R Cutter; Robert J Fox; Amber Salter
Journal:  Mult Scler J Exp Transl Clin       Date:  2022-05-22

4.  How Multiple Sclerosis Symptoms Vary by Age, Sex, and Race/Ethnicity.

Authors:  Ilya Kister; Tamar Bacon; Gary R Cutter
Journal:  Neurol Clin Pract       Date:  2021-08

5.  Cognitive Performance and Health-Related Quality of Life in Patients with Neuromyelitis Optica Spectrum Disorder.

Authors:  Elisabet Lopez-Soley; Jose E Meca-Lallana; Sara Llufriu; Yolanda Blanco; Rocío Gómez-Ballesteros; Jorge Maurino; Francisco Pérez-Miralles; Lucía Forero; Carmen Calles; María L Martinez-Gines; Inés Gonzalez-Suarez; Sabas Boyero; Lucía Romero-Pinel; Ángel P Sempere; Virginia Meca-Lallana; Luis Querol; Lucienne Costa-Frossard; Maria Sepulveda; Elisabeth Solana
Journal:  J Pers Med       Date:  2022-05-02

6.  Predictors of hospital-based multidisciplinary rehabilitation effects in persons with multiple sclerosis: a large-scale, single-centre study.

Authors:  Elisabetta Groppo; Alessio Signori; Maria Pia Sormani; Cristina Grosso; Loredana La Mantia; Davide Cattaneo; Marco Rovaris
Journal:  Mult Scler J Exp Transl Clin       Date:  2019-04-16

7.  Comparing the MSIS-29 and the Health Utilities Index Mark III in Multiple Sclerosis.

Authors:  Ruth Ann Marrie; Casandra Dolovich; Gary R Cutter; Robert J Fox; Amber Salter
Journal:  Front Neurol       Date:  2021-12-17       Impact factor: 4.003

8.  Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patients' Perspective: An Observational Cross-Sectional Study.

Authors:  José E Meca-Lallana; Rocío Gómez-Ballesteros; Francisco Pérez-Miralles; Lucía Forero; María Sepúlveda; Carmen Calles; María L Martínez-Ginés; Inés González-Suárez; Sabas Boyero; Lucía Romero-Pinel; Ángel P Sempere; Virginia Meca-Lallana; Luis Querol; Lucienne Costa-Frossard; Daniel Prefasi; Jorge Maurino
Journal:  Neurol Ther       Date:  2022-05-06

9.  Which symptoms contribute the most to patients' perception of health in multiple sclerosis?

Authors:  Rivka Green; Gary Cutter; Michael Friendly; Ilya Kister
Journal:  Mult Scler J Exp Transl Clin       Date:  2017-09-05

10.  Psychometric Properties of the SymptoMScreen Questionnaire in a Mild Disability Population of Patients with Relapsing-Remitting Multiple Sclerosis: Quantifying the Patient's Perspective.

Authors:  José Meca-Lallana; Jorge Maurino; Miguel Ángel Hernández-Pérez; Ángel P Sempere; Luis Brieva; Elena García-Arcelay; María Terzaghi; Gustavo Saposnik; Javier Ballesteros
Journal:  Neurol Ther       Date:  2020-01-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.